{"id":55673,"date":"2023-04-11T14:05:39","date_gmt":"2023-04-11T12:05:39","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/objectivehealth-announces-30th-research-center-of-excellence\/"},"modified":"2023-04-11T14:05:39","modified_gmt":"2023-04-11T12:05:39","slug":"objectivehealth-announces-30th-research-center-of-excellence","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/objectivehealth-announces-30th-research-center-of-excellence\/","title":{"rendered":"ObjectiveHealth Announces 30th Research Center of Excellence"},"content":{"rendered":"
\n

\nNashville-based research and technology company currently has <\/i>active research centers in 16 states across the country<\/i><\/p>\n

NASHVILLE, Tenn.–(BUSINESS WIRE)–#amarillo<\/a>—ObjectiveHealth<\/a>, a Nashville-based integrated research and technology platform company, today announced the opening of its 30th research site, Amarillo Premier Research<\/a>, in Amarillo, Texas.<\/p>\n

<\/a><\/p>\n

\nSince establishing its first research center in Nashville in 2018, ObjectiveHealth has expanded to 30 cities across 16 states, providing clinical research focused in the therapeutic areas of gastroenterology, dermatology, urology, oncology, biomarkers and metabolism disorders. Over 70 percent of its centers are located in smaller cities or rural communities, enabling it to reach the most diverse population possible.<\/p>\n

\nWorking in partnership with ObjectiveHealth, physicians are able to stay focused on patient care without becoming enmeshed in issues unrelated to their clinical practice. Through the addition of clinical research as a care option, physicians are able to grow and differentiate their practices from others in their region.<\/p>\n

\n\u201cClinical research will help lead us to answers for some of the most urgent healthcare challenges we face in our society,\u201d said Colleen Hoke, co-founder and chief executive officer of ObjectiveHealth. \u201cReaching this milestone of 30 sites supports one of our key goals of expanding our reach: offering the opportunity to participate in research to an ever-broader patient population.\u201d<\/p>\n

\nObjectiveHealth\u2019s partnership model places its teams within the footprints of existing physician practices, enabling a seamless integration of clinical research where patients are at the forefront of the overall care process. This model not only supports doctors, but also supports their patients and where they live, resulting in a higher retention rate than the industry standard. Patients are able to receive new and innovative treatments not available outside of the clinical research process.<\/p>\n

\n\u201cAt ObjectiveHealth, our unique approach to clinical research is centered around the patient experience, while also providing clear benefits for physicians and, ultimately, trial sponsors,\u201d said Don Lazas, MD, co-founder and chief medical officer of ObjectiveHealth. \u201cCombined with our innovative technology designed to streamline the research process and provide additional clarity to stakeholders, we aim to create the ideal environment to continue advancing medical research.\u201d<\/p>\n

\nWith the addition of Amarillo Premier Research, ObjectiveHealth now has four partnered research sites in Texas. Its other research sites in Texas are GMA Health Research<\/a> in Graham, Digestive Research of Central Texas<\/a> in Waco and Digestive Health Research of North Texas<\/a> in Wichita Falls.<\/p>\n

\nABOUT OBJECTIVEHEALTH<\/b><\/p>\n

\nObjectiveHealth<\/a> is a leading integrated research provider, partnering with physicians and healthcare organizations to establish an advanced infrastructure for research programs. The company takes an innovative approach to research that aims to improve patient outcomes at the point of care. Utilizing proprietary health-record-integrated technology, processes and trained on-site personnel, ObjectiveHealth delivers significant advances in the conduct of clinical research, benefiting clients and partners while providing broader care options for patients. With 30 partnered programs across 16 states and more than 600 providers, ObjectiveHealth is poised for continued growth due to the realized value of its healthcare solutions for all stakeholders. To learn more, visit objective.health<\/a>.<\/p>\n

Contacts<\/b> <\/p>\n

\nJonathan Houghton
\n
615-515-4892
\n
jhoughton@daltonagency.com<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Nashville-based research and technology company currently has active research centers in 16 states across the country NASHVILLE, Tenn.–(BUSINESS WIRE)–#amarillo—ObjectiveHealth, a Nashville-based integrated research and technology platform company, today announced the opening of its 30th research site, Amarillo Premier Research, in Amarillo, Texas. Since establishing its first research center in Nashville in 2018, ObjectiveHealth has expanded … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55673","6":"format-standard","7":"category-industry"},"yoast_head":"\nObjectiveHealth Announces 30th Research Center of Excellence - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/objectivehealth-announces-30th-research-center-of-excellence\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ObjectiveHealth Announces 30th Research Center of Excellence - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Nashville-based research and technology company currently has active research centers in 16 states across the country NASHVILLE, Tenn.–(BUSINESS WIRE)–#amarillo—ObjectiveHealth, a Nashville-based integrated research and technology platform company, today announced the opening of its 30th research site, Amarillo Premier Research, in Amarillo, Texas. Since establishing its first research center in Nashville in 2018, ObjectiveHealth has expanded ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/objectivehealth-announces-30th-research-center-of-excellence\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-11T12:05:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230411005109\/en\/1759116\/21\/ObjectiveHealth_logo_tag_RGB.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/objectivehealth-announces-30th-research-center-of-excellence\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/objectivehealth-announces-30th-research-center-of-excellence\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"ObjectiveHealth Announces 30th Research Center of Excellence\",\"datePublished\":\"2023-04-11T12:05:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/objectivehealth-announces-30th-research-center-of-excellence\\\/\"},\"wordCount\":510,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/objectivehealth-announces-30th-research-center-of-excellence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230411005109\\\/en\\\/1759116\\\/21\\\/ObjectiveHealth_logo_tag_RGB.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/objectivehealth-announces-30th-research-center-of-excellence\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/objectivehealth-announces-30th-research-center-of-excellence\\\/\",\"name\":\"ObjectiveHealth Announces 30th Research Center of Excellence - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/objectivehealth-announces-30th-research-center-of-excellence\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/objectivehealth-announces-30th-research-center-of-excellence\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230411005109\\\/en\\\/1759116\\\/21\\\/ObjectiveHealth_logo_tag_RGB.jpg\",\"datePublished\":\"2023-04-11T12:05:39+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/objectivehealth-announces-30th-research-center-of-excellence\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/objectivehealth-announces-30th-research-center-of-excellence\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/objectivehealth-announces-30th-research-center-of-excellence\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230411005109\\\/en\\\/1759116\\\/21\\\/ObjectiveHealth_logo_tag_RGB.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230411005109\\\/en\\\/1759116\\\/21\\\/ObjectiveHealth_logo_tag_RGB.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/objectivehealth-announces-30th-research-center-of-excellence\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"ObjectiveHealth Announces 30th Research Center of Excellence\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"ObjectiveHealth Announces 30th Research Center of Excellence - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/objectivehealth-announces-30th-research-center-of-excellence\/","og_locale":"en_US","og_type":"article","og_title":"ObjectiveHealth Announces 30th Research Center of Excellence - Pharma Trend","og_description":"Nashville-based research and technology company currently has active research centers in 16 states across the country NASHVILLE, Tenn.–(BUSINESS WIRE)–#amarillo—ObjectiveHealth, a Nashville-based integrated research and technology platform company, today announced the opening of its 30th research site, Amarillo Premier Research, in Amarillo, Texas. Since establishing its first research center in Nashville in 2018, ObjectiveHealth has expanded ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/objectivehealth-announces-30th-research-center-of-excellence\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-11T12:05:39+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230411005109\/en\/1759116\/21\/ObjectiveHealth_logo_tag_RGB.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/objectivehealth-announces-30th-research-center-of-excellence\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/objectivehealth-announces-30th-research-center-of-excellence\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"ObjectiveHealth Announces 30th Research Center of Excellence","datePublished":"2023-04-11T12:05:39+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/objectivehealth-announces-30th-research-center-of-excellence\/"},"wordCount":510,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/objectivehealth-announces-30th-research-center-of-excellence\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230411005109\/en\/1759116\/21\/ObjectiveHealth_logo_tag_RGB.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/objectivehealth-announces-30th-research-center-of-excellence\/","url":"https:\/\/pharma-trend.com\/en\/objectivehealth-announces-30th-research-center-of-excellence\/","name":"ObjectiveHealth Announces 30th Research Center of Excellence - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/objectivehealth-announces-30th-research-center-of-excellence\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/objectivehealth-announces-30th-research-center-of-excellence\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230411005109\/en\/1759116\/21\/ObjectiveHealth_logo_tag_RGB.jpg","datePublished":"2023-04-11T12:05:39+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/objectivehealth-announces-30th-research-center-of-excellence\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/objectivehealth-announces-30th-research-center-of-excellence\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/objectivehealth-announces-30th-research-center-of-excellence\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230411005109\/en\/1759116\/21\/ObjectiveHealth_logo_tag_RGB.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230411005109\/en\/1759116\/21\/ObjectiveHealth_logo_tag_RGB.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/objectivehealth-announces-30th-research-center-of-excellence\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"ObjectiveHealth Announces 30th Research Center of Excellence"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55673","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55673"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55673\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55673"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55673"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55673"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}